IGF-I Receptor Inhibition Combined with Rapamycin or Temsirolimus Inhibits Neuroblastoma Cell Growth

Background: Neuroblastoma is the third most common solid tumor in children. Treatment continues to be challenging. The pathogenesis of neuroblastoma has been related to expression of the type 1 insulin-like growth factor receptor (IGF1R) and to transcription factor MYC-N amplification. Previous stud...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2008-05, Vol.28 (3A), p.1509-1516
Hauptverfasser:	COULTER, Don W, BLATT, Julie, D'ERCOLE, A. Joseph, MOATS-STAATS, Billie M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Biological and medical sciences Cell Growth Processes - drug effects Cell Growth Processes - physiology Cell Line, Tumor Humans Medical sciences Neuroblastoma - drug therapy Neuroblastoma - metabolism Neuroblastoma - pathology Neurology Protein Kinases - metabolism Receptor, IGF Type 1 - antagonists & inhibitors Receptor, IGF Type 1 - metabolism Signal Transduction - drug effects Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sirolimus - pharmacology TOR Serine-Threonine Kinases Tumors Tumors of the nervous system. Phacomatoses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!